沙利度胺在人类免疫缺陷病毒感染患者中的单剂量药代动力学。
Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.
作者信息
Piscitelli S C, Figg W D, Hahn B, Kelly G, Thomas S, Walker R E
机构信息
Department of Pharmacy, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA.
出版信息
Antimicrob Agents Chemother. 1997 Dec;41(12):2797-9. doi: 10.1128/AAC.41.12.2797.
Abstract
The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.
摘要
研究了沙利度胺在9例人类免疫缺陷病毒感染患者中的药代动力学。单剂量沙利度胺吸收良好，100毫克和300毫克给药组的平均峰值浓度（±标准差）分别为1.17±0.21和3.47±1.14微克/毫升，平均消除半衰期约为6小时。不良反应轻微，9例患者中有7例报告有嗜睡症状。
相似文献
1
Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.沙利度胺在人类免疫缺陷病毒感染患者中的单剂量药代动力学。
Antimicrob Agents Chemother. 1997 Dec;41(12):2797-9. doi: 10.1128/AAC.41.12.2797.
2
Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects.
AIDS Res Hum Retroviruses. 1999 Aug 10;15(12):1047-52. doi: 10.1089/088922299310331.
3
Population Pharmacokinetic Model to Assess the Impact of Disease State on Thalidomide Pharmacokinetics.评估疾病状态对沙利度胺药代动力学影响的群体药代动力学模型。
J Clin Pharmacol. 2020 Jan;60(1):67-74. doi: 10.1002/jcph.1506. Epub 2019 Aug 7.
4
Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.口服左氧氟沙星在接受齐多夫定治疗的人类免疫缺陷病毒感染个体中的药代动力学和安全性。
Antimicrob Agents Chemother. 1997 Aug;41(8):1765-9. doi: 10.1128/AAC.41.8.1765.
5
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267.
J Infect Dis. 2002 May 1;185(9):1359-63. doi: 10.1086/340133. Epub 2002 Apr 16.
6
Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients.左氧氟沙星高剂量及延长给药间隔方案在人类免疫缺陷病毒感染患者中的药代动力学及安全性
Antimicrob Agents Chemother. 1999 Sep;43(9):2323-7. doi: 10.1128/AAC.43.9.2323.
7
Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics.
Clin Pharmacol Ther. 1999 May;65(5):483-90. doi: 10.1016/S0009-9236(99)70067-6.
8
Thalidomide is distributed into human semen after oral dosing.口服给药后，沙利度胺会分布到人体精液中。
Drug Metab Dispos. 2001 Oct;29(10):1355-7.
9
Pharmacokinetics of thalidomide in an elderly prostate cancer population.
J Pharm Sci. 1999 Jan;88(1):121-5. doi: 10.1021/js980172i.
10
Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group.沙利度胺在接受口腔阿弗他溃疡治疗的HIV患者中的药代动力学和药效学：ACTG方案251。艾滋病临床试验组。
J Clin Pharmacol. 2001 Oct;41(10):1091-7. doi: 10.1177/00912700122012698.
引用本文的文献
1
Thalidomide-induced limb malformations: an update and reevaluation.沙利度胺所致肢体畸形：最新进展与重新评估
Arch Toxicol. 2025 May;99(5):1643-1747. doi: 10.1007/s00204-024-03930-z. Epub 2025 Apr 8.
2
Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies.利用基于机制的生理药代动力学模型评估产前药物暴露：以沙利度胺和依非韦伦为例。
Eur J Pharm Sci. 2019 Dec 1;140:105068. doi: 10.1016/j.ejps.2019.105068. Epub 2019 Sep 10.
3
Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production.基于重定位的药物筛选发现驱虫药尼氯硝唑是一种抗骨髓瘤疗法，也能减少游离轻链的产生。
Blood Cancer J. 2011 Oct;1(10):e39. doi: 10.1038/bcj.2011.38. Epub 2011 Oct 21.
4
Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.在非人灵长类动物中沙利度胺和来那度胺的血浆和脑脊液药代动力学。
Cancer Chemother Pharmacol. 2012 Apr;69(4):943-7. doi: 10.1007/s00280-011-1781-y. Epub 2011 Nov 23.
5
Transport of thalidomide by the human intestinal caco-2 monolayers.沙利度胺在人肠Caco-2单层细胞中的转运。
Eur J Drug Metab Pharmacokinet. 2005 Jan-Jun;30(1-2):49-61. doi: 10.1007/BF03226408.
6
Clinical pharmacokinetics of thalidomide.沙利度胺的临床药代动力学
Clin Pharmacokinet. 2004;43(5):311-27. doi: 10.2165/00003088-200443050-00004.
7
Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide.沙利度胺对大肠杆菌实验性败血症的有效免疫调节治疗
Antimicrob Agents Chemother. 2003 Aug;47(8):2445-9. doi: 10.1128/AAC.47.8.2445-2449.2003.
8
Thalidomide as an anti-cancer agent.沙利度胺作为一种抗癌药物。
J Cell Mol Med. 2002 Apr-Jun;6(2):160-74. doi: 10.1111/j.1582-4934.2002.tb00184.x.
9
Thalidomide in cancer treatment: a potential role in the elderly?沙利度胺在癌症治疗中的作用：对老年人有潜在作用吗？
Drugs Aging. 2002;19(2):85-100. doi: 10.2165/00002512-200219020-00002.
10
Thalidomide in gastrointestinal disorders.
Drugs. 2001;61(6):777-87. doi: 10.2165/00003495-200161060-00006.
本文引用的文献
1
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.沙利度胺用于治疗人类免疫缺陷病毒感染患者的口腔阿弗他溃疡。美国国立过敏与传染病研究所艾滋病临床试验组。
N Engl J Med. 1997 May 22;336(21):1487-93. doi: 10.1056/NEJM199705223362103.
2
Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: case report and review.沙利度胺治疗人类免疫缺陷病毒感染者口腔阿弗他溃疡：病例报告及文献复习
Am J Gastroenterol. 1997 Jan;92(1):169-70.
3
Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.沙利度胺对与HIV相关的消瘦综合征的影响：一项随机、双盲、安慰剂对照临床试验。
AIDS. 1996 Nov;10(13):1501-7. doi: 10.1097/00002030-199611000-00007.
4
Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus.
Am J Health Syst Pharm. 1996 Feb 15;53(4):368, 371-2, 378. doi: 10.1093/ajhp/53.4.368.
5
Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1.嵌合抗体对感染1型人类免疫缺陷病毒患者免疫反应性肿瘤坏死因子-α的抑制作用
J Infect Dis. 1996 Jul;174(1):63-8. doi: 10.1093/infdis/174.1.63.
6
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.沙利度胺通过增强信使核糖核酸降解对肿瘤坏死因子α发挥抑制作用。
J Exp Med. 1993 Jun 1;177(6):1675-80. doi: 10.1084/jem.177.6.1675.
7
In vitro activity of thalidomide against Mycobacterium avium complex.沙利度胺对鸟分枝杆菌复合群的体外活性。
Arch Intern Med. 1993 Feb 22;153(4):534.
8
Thalidomide inhibits the replication of human immunodeficiency virus type 1.沙利度胺抑制1型人类免疫缺陷病毒的复制。
Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):5974-8. doi: 10.1073/pnas.90.13.5974.
9
The treatment of microsporidial diarrhoea with thalidomide.沙利度胺治疗微孢子虫性腹泻
AIDS. 1995 Jun;9(6):658-9. doi: 10.1097/00002030-199506000-00025.
10
Stability of thalidomide in human plasma.沙利度胺在人血浆中的稳定性。
Clin Chem. 1995 Aug;41(8 Pt 1):1199.
Zotero 插件